Executive Summary

Keros Therapeutics, Inc. (KROS) relies heavily on a small set of suppliers and customers, with two key partners—Takeda Pharmaceuticals and Hansoh—holding high confidence in their relationships. This concentration introduces material supply chain risk, particularly as Keros is dependent on these entities for both product development and commercialization. The company's revenue is also concentrated among a handful of customers, suggesting limited pricing power and potential exposure to client-specific volatility.

Supplier Analysis

Top Suppliers by Confidence

The most critical suppliers for Keros are those with confidence scores above 0.80, indicating strong alignment with SEC filings or verified relationships.

  • TAKEDA-PHARMACEUTICALS-U-S-A-INC [confidence: 0.90] – Takeda is a key partner in the commercialization of elritercept, as highlighted in the Hansoh Agreement and a separate license agreement. This supplier is essential for regulatory and commercial success.
  • HANSOH-SHANGHAI-HEALTHTECH-CO-LTD [confidence: 0.90] – Hansoh is central to the commercialization of elritercept and is named in multiple SEC filings as a critical collaborator. Its high confidence score indicates a verified and material role in Keros' operations.

Other Suppliers

Several suppliers, including Scholar Rock (SRRK), Regeneron (REGN), and Bristol-Myers Squibb (BMY), have confidence scores of 0.72, suggesting inferred or less-documented relationships. While these may support Keros' pipeline, their role is less certain and may reflect internal development or limited commercial engagement.

Concentration Risk

Keros’ supply chain is highly concentrated, with Takeda and Hansoh representing the most critical suppliers. The remaining 12 suppliers, while diverse in name, are not clearly differentiated in terms of their strategic importance, suggesting limited diversification and potential operational vulnerability.

Customer Analysis

Top Customers

Keros’ customer base is similarly concentrated, with Hansoh and Massachusetts General Hospital (MGH) standing out for their high confidence scores.

  • HANSOH-SHANGHAI-HEALTHTECH-CO-LTD [confidence: 0.92] – Hansoh is the most significant customer, as it is purchasing clinical trial supplies of elritercept. This relationship is central to Keros’ near-term revenue and development.
  • MASSACHUSETTS-GENERAL-HOSPITAL [confidence: 0.90] – MGH is involved in the design of a Phase 2 trial for rinvatercept, indicating a strategic partnership with potential for future revenue generation.

Revenue Concentration

While the remaining 12 customers have confidence scores of 0.72, the lack of differentiation suggests limited revenue contribution from non-top-tier customers. This concentration may limit Keros’ ability to negotiate favorable terms and expose it to client-specific risk.

Significance of the Mix

The dominance of a few key customers signals that Keros may lack pricing power, as it is likely dependent on strategic partnerships rather than market-driven demand. This dynamic could limit revenue stability and growth potential unless Keros diversifies its customer base.

Supply Chain Risks

Single-Source Dependencies

Keros’ supply chain is heavily dependent on Takeda and Hansoh for both development and commercialization, creating a single-source risk. The SEC filing states, “We are dependent on our existing third-party collaborations with Takeda and Hansoh to commercial elritercept,” highlighting the critical role these entities play in the company’s success.

Regulatory and Compliance Risks

Several suppliers, including Edgewise, Sarepta, and Bristol-Myers Squibb, are noted in SEC filings to be subject to “continued regulatory review,” which could result in delays, increased costs, or penalties. The exact wording from the filings is: “nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with such product candidate.” This language reflects the broader regulatory environment in which Keros operates.

Geographic Exposure

Keros’ supply chain is geographically diverse, with U.S.-based and international suppliers. However, the lack of specific geographic breakdowns in the data limits the ability to assess regional risk exposure.

Investor Takeaways

Margin Impact: Keros’ reliance on a small number of suppliers and customers may limit its ability to negotiate favorable terms, potentially compressing margins. The high dependency on Takeda and Hansoh could lead to revenue concentration and pricing pressure.

Revenue Stability: The concentration of revenue among a few customers, particularly Hansoh, introduces volatility. Any disruption in these relationships could significantly impact Keros’ financial performance.

Growth Prospects: Keros’ growth is tied to the success of its clinical candidates, which are subject to ongoing regulatory review. The company may face delays or increased costs if its suppliers encounter regulatory issues, as noted in the SEC filings.

Strategic Implications: Investors should monitor the company’s efforts to diversify its supplier and customer base. A more balanced supply chain could reduce risk and improve long-term financial resilience.